Drugs / Autologous Tumor Infiltrating Lymphocytes
Autologous Tumor Infiltrating Lymphocytes
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05903937 | Jan 2027 → Dec 2029 expected | metastatic melanoma, uveal melanoma | Vastra Gotaland Region | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04812470 | Feb 2023 → May 2025 | cutaneous melanoma, uveal melanoma | Vastra Gotaland Region | Completed | No outcome recorded |
| Phase 1 | NCT03991741 | Oct 2020 → Jan 2023 | head and neck cancer, metastatic melanoma | Gregory Daniels | Terminated | No outcome recorded |
| Phase 1 | NCT06084299 | May 2020 → Aug 2026 overdue | liver cancer | Zhiyong Huang | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05152797 | Jan 2022 → Jan 2024 overdue | — | Women's Hospital School Of Medicine Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT03296137 | Oct 2017 → Mar 2020 | cancer | Inge Marie Svane | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07560111 | Jun 2026 → Jun 2027 expected | non-small cell lung carcinoma | Shanghai Juncell Therapeutics | Not yet recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT01005537 | Jun 2009 → Oct 2010 | cutaneous melanoma | Fred Hutchinson Cancer Center | No longer available | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-20 | Shanghai Juncell Therapeutics | Results 挑战“癌中之王”，TIL 疗法守护生命“胰”线希望 juncell.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-20 | Shanghai Juncell Therapeutics | 挑战“癌中之王”，TIL 疗法守护生命“胰”线希望 juncell.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous tumor-infiltrating lymphocytes | “Patients receive cyclophosphamide IV on days -3 and -2 and autologous tumor-infiltrating lymphocytes (TIL) IV on day 0.” NCT01005537 ↗ |
| Known as | TIL | “Patients receive cyclophosphamide IV on days -3 and -2 and autologous tumor-infiltrating lymphocytes (TIL) IV on day 0.” NCT01005537 ↗2“autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion” NCT05903937 ↗ “Autologous TIL administered via hepatic arterial infusion” NCT04812470 ↗ |
| Known as | TILs | “Adoptive cell transfer of autologous tumor-infiltrating lymphocytes (TILs) has been shown to induce responses in a subset of patients with metastatic uveal melanoma.” PMID 41850738 ↗ Mar 20261“Autologous tumor-infiltrating lymphocytes (TILs) infusion is highly personalized cancer immunotherapy with strong anti-tumor efficacy and tumor specificity.” NCT05152797 ↗ |
| Modality | Cell therapy | “cellular adoptive immunotherapy using autologous lymphocytes” NCT01005537 ↗ |
| Route | Intravenous | “autologous tumor-infiltrating lymphocytes (TIL) IV on day 0” NCT01005537 ↗ |